Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02575404 · ClinicalTrials.gov registry record · Phase 1
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients
A Phase 1 study, sponsored by Providence Health & Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT02575404 is a Phase 1 study that has completed, run by Providence Health & Services. The registered enrollment target is 36 participants.
The verdict
NCT02575404, a Phase 1 study, has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This study is a dose escalation of GR-MD-02 with the standard therapeutic dose of pembrolizumab in patients with advanced melanoma, non-small cell lung cancer, and head and neck squamous cell cancer.
Interventions
- DRUG Pembrolizumab
- DRUG GR-MD-02
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2016-05-16 |
| Est. Completion | 2022-10-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02575404
The ClinicalTrials.gov registry entry for NCT02575404 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02575404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02575404 about?
NCT02575404 is a clinical study titled "GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients". This study is a dose escalation of GR-MD-02 with the standard therapeutic dose of pembrolizumab in patients with advanced melanoma, non-small cell lung cancer, and head and neck squamous cell cancer.
What is the current status of trial NCT02575404?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2016-05-16. Estimated completion is 2022-10-10.
What interventions are being tested in trial NCT02575404?
The interventions under investigation include: Pembrolizumab (DRUG), GR-MD-02 (DRUG).
Who is sponsoring clinical trial NCT02575404?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.